A large long‑term study tracking older adults in Wales has found that seniors with dementia who received the shingles vaccine were substantially less likely to die from dementia compared with those who did not receive the shot.
The research examined more than 14,000 seniors living with dementia at the start of the vaccination programme. Over a nine‑year follow‑up period roughly half of them died from dementia.
Among those who had received the vaccine the risk of dementia‑related death was almost 30 percentage points lower, indicating a significant association between immunisation and improved dementia outcomes.
Earlier findings from the same population had shown that older adults vaccinated with the shingles shot before dementia onset were approximately 20 percent less likely to develop dementia compared to peers who were not vaccinated.
Though the protective mechanism remains uncertain, researchers behind the study suggest that beyond preventing shingles outbreaks the vaccine may influence processes related to neurodegeneration — possibly delaying disease progression or improving survival once dementia has been diagnosed.
This emerging evidence strengthens the idea that vaccination against the virus responsible for shingles could have broader benefits for brain health. If confirmed by further research, the findings may open new avenues for dementia prevention and management in aging populations.
Also Read